tert-butyl-(5-ethoxy-2-fluoro-phenoxy)-dimethyl-silane | 577793-67-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: tert-butyl-(5-ethoxy-2-fluoro-phenoxy)-dimethyl-silane
• 英文别名: tert-Butyl(5-ethoxy-2-fluorophenoxy)dimethylsilane；tert-butyl-(5-ethoxy-2-fluorophenoxy)-dimethylsilane
• CAS: 577793-67-0
• 化学式: C₁₄H₂₃FO₂Si
• 分子量: 270.419
• InChiKey: XTDJHWMCTPUDAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.61
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl-(5-ethoxy-2-fluoro-phenoxy)-dimethyl-silane 在 正丁基锂 、 五甲基二乙烯三胺 、 硼酸三甲酯 、 盐酸 、 水 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 2.0h， 以72%的产率得到3-(tert-Butyldimethylsilyloxy)-5-ethoxy-2-fluorophenylboronic acid
  参考文献：
  名称：

  Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants

  摘要：

  本发明提供了式(I)或(IV)的新型苯基甘氨酰衍生物：或其立体异构体、互变异构体、药学上可接受的盐、溶剂合物或前药，其中变量W、W1、Y、Z、R7、R8、R9和R11如本文所定义。这些化合物是选择性因子VIIa的抑制剂，可用作药物。

  公开号：

  US20070003539A1
• 作为产物：
  描述：

  4-氟苯乙醚 在 咪唑 、 正丁基锂 、 五甲基二乙烯三胺 作用下， 以 四氢呋喃 、 正己烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 tert-butyl-(5-ethoxy-2-fluoro-phenoxy)-dimethyl-silane
  参考文献：
  名称：

  Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensity

  摘要：

  The discovery of a highly potent and selective tissue factor/factor VIIa inhibitor is described. Upon oral administration of its double prodrug in the guinea pig, a dose-dependent antithrombotic effect is observed in an established model of arterial thrombosis without prolonging bleeding time. The pharmacodynamic properties of this selective inhibitor are compared to the behaviour of a mixed factor VIIa/factor Xa inhibitor. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.03.042

文献信息

• N-(4-CARBAMIMIDOYL-PHENYL)-GLYCINE DERIVATIVES
  申请人：——

  公开号：US20030166683A1

  公开（公告）日：2003-09-04

  The invention is concerned with water soluble N—(4-carbamimidoyl-phenyl)-glycine derivatives of formula (I) 1 wherein R 1 to R 4 and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the formation of coagulation factors Xa, IXa and thrombin induced by factor VIIa and tissue factor and can be used as medicaments.

  本发明涉及水溶性的公式(I)1中的N-(4-氨基甲酰基苯基)甘氨酸衍生物，其中R1至R4和n如说明和权利要求中所定义，以及其生理上可接受的盐。这些化合物能抑制由因子VIIa和组织因子诱导的凝血因子Xa、IXa和凝血酶的形成，可用作药物。
• N-(4-carbamimidoyl-phenyl)-glycine derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US06642386B2

  公开（公告）日：2003-11-04

  The invention is concerned with water soluble N-(4-carbamimidoyl-phenyl)-glycine derivatives of formula (I) wherein R1 to R4 and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the formation of coagulation factors Xa, IXa and thrombin induced by factor VIIa and tissue factor and can be used as medicaments.

  本发明涉及水溶性的N-(4-氨基甲酰基苯基)-甘氨酸衍生物，其化学式为(I)，其中R1至R4和n的定义如说明书和权利要求所述，以及其生理上可接受的盐。这些化合物抑制因子VIIa和组织因子诱导的凝血因子Xa、IXa和凝血酶的形成，可用作药物。
• Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensity
  作者：Katrin Groebke Zbinden、David W. Banner、Kurt Hilpert、Jacques Himber、Thierry Lavé、Markus A. Riederer、Martin Stahl、Thomas B. Tschopp、Ulrike Obst-Sander

  DOI：10.1016/j.bmc.2006.03.042

  日期：2006.8

  The discovery of a highly potent and selective tissue factor/factor VIIa inhibitor is described. Upon oral administration of its double prodrug in the guinea pig, a dose-dependent antithrombotic effect is observed in an established model of arterial thrombosis without prolonging bleeding time. The pharmacodynamic properties of this selective inhibitor are compared to the behaviour of a mixed factor VIIa/factor Xa inhibitor. (c) 2006 Elsevier Ltd. All rights reserved.
• Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
  申请人：Zhang Xiaojun

  公开号：US20070003539A1

  公开（公告）日：2007-01-04

  The present invention provides novel phenylglycinamide derivatives of Formula (I) or (IV): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables W, W 1 , Y, Z, R 7 , R 8 , R 9 , and R 11 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

  本发明提供了式(I)或(IV)的新型苯基甘氨酰衍生物：或其立体异构体、互变异构体、药学上可接受的盐、溶剂合物或前药，其中变量W、W1、Y、Z、R7、R8、R9和R11如本文所定义。这些化合物是选择性因子VIIa的抑制剂，可用作药物。